The apolipoprotein E (APOE, gene; apoE, protein) type 4 isoform is a well-established risk factor for late-onset Alzheimer's disease (AD), and new data suggest that APOE promoter polymorphisms might also modulate AD risk, perhaps by altering transcription of the APOE gene. The current study was undertaken to determine whether the presence of the APOE promoter −491AA genotype (that appears to increase the risk for AD) is associated with an increase in the levels of apoE in brain tissue. Among 40 control and 20 autopsy-confirmed AD brain samples, levels of apoE were increased in the frontal cortex of AD cases (P Ͻ 0.001), consistent with the well-recognized up-regulation of APOE expression in reactive astrocytes. Among controls, the −491A allele appeared to impart a gene dose-dependent effect on the levels of apoE in frontal cortex. The levels of apoE in the brains of AD patients with the −491AA genotype were increased as compared to control subjects with the same genotype (P Ͻ 0.001). These data support the notion that the −491AA APOE promoter genotype is associated with elevated brain apolipoprotein E levels, suggesting that the risk for AD may be modulated by the apoE protein level as well as by the apoE protein isoform.
Introduction
Human apolipoprotein E (apoE) is encoded by the APOE gene on the long arm of chromosome 19 (19q13.2) and is one of several classes of lipoproteins that transport lipids in plasma and other body fluids. 1 Plasma apoE is synthesised primarily in the liver, whereas astrocytes are responsible for its synthesis in the brain, where it is the major apolipoprotein.
2,3 ApoE exists in three major isoforms, denoted as apoE2, apoE3 and apoE4 which arise from three APOE alleles, denoted as APOE-⑀2, APOE-⑀3 and APOE-⑀4, located at the single gene locus on chromosome 19 (see Zannis et al, 1982 4 for clarification of nomenclature of apoE). The expression of these three alleles will either give rise to one of three homozygous genotypes (APOE-⑀2/⑀2, APOE-⑀3/⑀3 and APOE-⑀4/⑀4) or three hetero- 
APOE-⑀2/⑀4).
Substantial evidence implicates apolipoprotein E polymorphisms in modulating the risk for Alzheimer's disease (AD). The ⑀4 allele is significantly over-represented in AD, 5, 6 where it appears to increase risk for AD in a gene dose-dependent manner. 7 In addition to the influence of APOE genotype, recent evidence has indicated that regulation of APOE expression may also contribute to the pathogenesis of AD. Initial clues to the existence of this relationship were based on observations that plasma apoE levels were elevated in individuals suffering from AD. 8 Subsequent studies showed an association of APOE promoter polymorphisms with increased risk of developing AD. [9] [10] [11] [12] [13] Increased levels of plasma apoE are associated with the AA genotype of the −491A/T promoter polymorphism, but plasma levels might not accurately reflect apoE levels in the brain. Since AD is a brain disorder, it was important to determine whether the −491AA genotype is associated with increased brain apoE levels. We report here that the AA genotype of the −491A/T promoter polymorphism is associated with elevated brain apoE levels in control and AD subjects.
Methods
With approval from our institute's ethics committee, we investigated the frequency of APOE genotypes and −491A/T APOE promoter polymorphism genotypes together with levels of apoE in 60 brain specimens collected from institutes in Perth (Hollywood Private Hospital), Melbourne (University of Melbourne and the Mental Health Research Institute) and Sydney (University of Sydney). AD cases were neuropathologically confirmed based on established ADRDA criteria (n = 20; 65.6 ± 3.3 years; male : female ratio 1.2 : 1; PMI = 21.5 ± 1.3 h) and consisted of 12 cases with age of onset greater than 65 and eight cases with an age of onset less than 65 years. Neuropathologicaly assessed control brains were from individuals with no known brain disease (n = 40; 61.2 ± 2.5 years; male : female ratio 1.35 : 1; PMI = 26.0 ± 3.8 h). Sections of prefrontal cortex were homogenized and used for studies of APOE genotypes and apoE protein.
Total DNA was extracted from brain tissue using standard protocols. APOE genotyping PCR was performed in a total volume of 15 l, containing 1. 14 The oligonucleotide primers, (P1) 5Ј-TCCAAGGAGCTGCAGGCGG CGCA-3Ј and (P2) 5Ј-ACAGAATTCGCCCCGGCCTGG TACACTGCCA-3Ј, were used as described by Wenham et al. 15 The amplified product was digested at 37°C using 5 U of the restriction enzyme HhaI and electrophoresed in an 8% non-denaturing polyacrylamide gel. Gels were then stained with ethidium bromide and viewed on an UV transilluminator to reveal DNA fragments with electrophoretic migration patterns unique to each allele. 15 The genotype of the APOE −491A/T polymorphism was determined via a two-stage PCR amplification, using the genomic primers (P1 (−1017) 5Ј-CAA GGT CAC ACA GCT GGC AAC-3Ј and P2 (+406) 5Ј-TCC AAT CGA CGG CTA GCT ACC-3Ј) and the nested primers (P1 (−285) 5Ј-TGT TGG CCA GGC TGG TTT TAA-3Ј and P2 (−512) 5Ј-CCT CCT TTC CTG ACC CTG TCC-3Ј) as described.
11 PCR was performed in a total volume of 20 l (genomic) or 15 l (nested), containing 1.0 U of Taq Polymerase, 0.2 mM of each dNTP and 1 mM of MgCl 2 , during 37 cycles. Briefly, 1 cycle of 94°C for 5 min; 35 cycles of 94°C for 30 s, 68°C for 2 min; 1 cycle of 94°C for 30 s, 68°C for 10 min, 4°C for 1 min. Amplified products were digested at 37°C using 5 U of the restriction enzyme DraI and visualised via ethidium bromide staining of the 8% non-denaturing polyacrylamide gel.
Approximately 250 mg of tissue was dissected from the prefrontal cortex and used for measurements of apoE protein levels. Tissue was homogenised in phosphate buffered saline (pH 7.4) with 5 g ml −1 aprotinin, Molecular Psychiatry 5 g ml −1 leupeptin and 0.1 M phenylmethylsulphonyl fluoride. Protein concentrations in the brain homogenates were determined by the BCA method (Pierce). Frontal cortex homogenates (25 g) were diluted 1:4 with sodium dodecyl sulfate (SDS) sample buffer (1 M Tris HCl pH 6.8, 8% w/v SDS, 4% w/v glycine), boiled for 5 min and proteins separated on 8-12% SDS-polyacrylamide gels, using recombinant human apoE ⑀4 (Panvera, USA) used as standard. Separated proteins were transferred overnight to nitrocellulose membranes (Biorad). Membranes were incubated with blocking solution (PBS pH 7.4, 0.5% w/v casein, 10 mM NaOH) for 45 min at room temperature, and then immersed in goat anti-human apoE (dilution 1:4000) for 2 h in PBS pH 7.4, both at room temperature. Membranes were then washed three times in wash buffer (TBS-T; 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% v/v Tween 20) and immersed in horseradish peroxidase-conjugated rabbit anti-goat IgG (DAKO) for 1 h in TBS-T pH 8.0 (dilution 1:4000). Membranes were then washed three times before chemiluminescent visualization was carried out using ECL reagent from Amersham and exposed to Amersham ECL Hyperfilm. Developed film was analyzed using a UMAX scanner, and apoE protein concentration was quantitated using NIH Image software, version 1.62. Differences in apoE levels were evaluated using the MannWhitney U test, applied to data derived from the linear region of apoE standard curves. Categorical variables were investigated using the Pearson method for the analysis of contingency ( 2 ).
Results and discussion
Genotypic distribution of both APOE and −491A/T genotype were consistent with the distribution predicted by the Hardy-Weinberg equilibrium (APOE: 2 test; P = 0.9; − 491: 2 test; P = 0.31). As expected, analysis of the frequency of APOE-⑀4 alleles revealed a strong association with AD (P = 0.005, 2 = 7.74; OR = 3.4, 95% CI 1.4-8.25) as compared to controls ( Table  1) . Analysis of the −491A allele also revealed a significant association with AD (P = 0.04, 2 = 4.27; OR = 3.2, 95% CI 1.02-10.08) when compared with controls ( Table 1) .
Levels of apoE in the frontal cortex of AD were significantly increased over that of control cases (MannWhitney U-test; P Ͻ 0.001; z = 4.93; Figure 1 ). Among control cases, the levels of apoE were significantly increased in individuals with the −491AA genotype when compared to individuals without this genotype (Mann-Whitney U-test; P = 0.002; z = 3.06; Figure 2 ). An apparent gene-dosage effect of the −491A allele on apoE levels was also apparent (−491AA Ͼ −491AT Ͼ −491TT; Figure 2 ). AD cases with the −491AA genotype had significantly increased frontal cortex apoE levels when compared to control cases with the corresponding genotype (Mann-Whitney U-test; P Ͻ 0.001; z = 3.53; Figure 2) , consistent with the well-recognized upregulation of APOE expression in reactive astrocytes in AD. APOE-⑀4 is universally recognised as the major identified genetic risk factor for the development of late-onset AD, with as many as 50% of individuals affected with AD bearing-an APOE-⑀4 allele. 6, 7 However, the ⑀4 allele is not sufficient to guarantee AD, since some individuals possessing two APOE-⑀4 alleles will escape AD.
Recently, a polymorphism in the regulatory region of the APOE gene was found to be associated with an increased risk for developing AD independent of that conveyed by the ⑀4 allele of APOE. 9, 17 We previously showed that plasma apoE levels were elevated in AD Figure 2 APOE −491A/T promoter polymorphisms and apoE levels in the frontal cortex. APOE −491A/T promoter polymorphisms and apoE levels in the frontal cortex of (a) control and (b) AD subjects as determined by quantitative Western Blot analysis. The −491A allele was found to impart a gene dose-dependent effect on apoE levels in the frontal cortex of control cases; AA (250.7 ± 8.6 ng mg −1 protein) Ͼ AT (217.9 ± 11.7 ng mg −1 protein) Ͼ TT (166.4 ± 9.1 ng mg −1 protein). This was not apparent in AD cases; AA = 360.5 ± 27.2 ng mg and that the AA genotype of the −491A/T promoter polymorphism may contribute to this elevation independent of ⑀4 status. 9 In this study, the correlation of increased apoE levels in brain with the −491AA genotype of the 491A/T promoter polymorphism extends and confirms our earlier data associating the −491 AA genotype with elevated plasma apoE levels. 9 The results are also consistent with the reports of the effect of the −491 promoter polymorphism on transcriptional activity. 10, 11 The effect of these polymorphisms on transcriptional activity was investigated via transient transfection assays in HepG2 10 and U87 cells. 11 The presence of the −491A allele resulted in the increased basal transcriptional activity of the APOE gene in both of these cell lines. As such, it presents a plausible explanation for our findings in the frontal cortex. These findings are also supported in the literature by reports that mRNA is increased in the frontal and temporal cortex 18, 19 as well as in the hippocampus 20 of neuropathologically confirmed AD cases. It is also supported by findings of increased soluble levels in the cerebellar cortex and increased bound apoE levels in the frontal cortex of AD brains. 21 Biological levels of apoE in brain tissue are a subject over which much conjecture remains, with varying reports on the levels of soluble, bound and total apoE reported. As such, larger studies, incorporating a larger pool of both late-and early-onset AD, need to be performed to elucidate the significance of the findings in this current study. It is plausible that, whilst the −491A allele is associated with an overall increase in apoE expression, the true impact of this allele may be seen in isoform-specific differences in the levels of expression. An example where this impact would be seen to a greater extent is in −491AT-APOE-⑀2/⑀4 individuals. In such a case the −491A allele may be coupled to the pathogenic APOE-⑀4 allele whilst the −491T allele is coupled with the APOE-⑀2 allele. This situation would result in a higher expression of the pathogenic isoform and as such place that individual at a greater risk than if the −491A allele was in fact coupled with the APOE-⑀2 allele. This hypothesis may account for the heterogeneity of impact of the APOE-⑀4 allele on AD risk.
The current study also suggests that the −491A allele exerts this action in a gene dosage-dependent manner. This effect was not observed in AD cases, possibly due to the well recognized several-fold up-regulation of APOE expression in reactive astrocytes in AD, 16 which may mask this effect due to case-to-case differences in the level of activation. However, to determine if this is the case or whether a gene-dosage effect is present, much larger numbers need to be analysed to overcome the expected high frequency of the −491AA genotype, as seen in this study. Thus, in addition to the APOE genotypes, due to polymorphisms affecting residues 112 and 158, the levels of apoE in the brain, as well as the factors that upregulate its expression, may also play a role in the pathogenesis of AD. This observation is supported by an independent line of investigation suggesting that apoE is required for the formation of cerebral amyloid plaques. [22] [23] [24] [25] These studies illustrated that, in the absence of apoE, APP717 transgenic mice did not form the characteristic pathology of this mouse model. Pathology was only seen to be evident in the presence of apoE. Thus, it is plausible that increased apoE levels may result in increased cerebral amyloid Molecular Psychiatry deposition. This hypothesis is supported by the −491AA genotype being shown to be associated with increased A␤40, A␤42 and total A␤ load in AD brains. 26 As such, it is possible that if apoE levels could be regulated, it may represent an effective means of delaying the onset of or diminishing the level of cerebral amyloidosis, which, in turn, should delay or prevent the onset of, or diminish the rate of, cognitive decline seen in AD.
